Targeted polymeric inflammation-resolving nanoparticles

US10314917B2 · kind B2 · utility

Assignees

• The Brigham and Women's Hospital, Inc. · US
• Massachusetts Institute of Technology · US
• The Trustees of Columbia University in the City of New York · US

Inventors

• Omid C. Farokhzad · Sharon, US
• Xueqing Zhang · Cambridge, US
• Xiaoyang Xu · Changchun, CN
• Nazila Kamaly · Boston, US
• Mingming Ma · Beijing, CN
• Pedro Valencia · Cambridge, US
• Robert S. Langer · Newton, US
• Ira Tabas · New York, US
• Gabrielle Beth Fredman · New York, US

Key dates

• Filing date: Mar 17, 2014
• Grant date: Jun 11, 2019
• Expiry date: Oct 3, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P37/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Sub-100 micron multimodal nanoparticles have four main components: 1) a target element (peptides, lipids, antibodies, small molecules, etc.) that can selectively bind to cells, tissues, or organs of the body; 2) a diagnostic agent such as a fluorophore or NMR contrast agent that allows visualization of nanoparticles at the site of delivery and/or a therapeutic or prophylactic agent; 3) an outside “stealth” layer that allows the particles to evade recognition by immune system components and increase particle circulation half-life; and 4) a biodegradable polymeric material, forming an inner core which can carry therapeutics and release the payloads at a sustained rate after systemic, intraperitoneal, or mucosal administration. These particles possess excellent stability, high loading efficiency, multiple agent encapsulation, targeting and imaging. They are targeted to sites of, or associated with, inflammation caused by a disease, disorder; trauma, chemotherapy or radiation.